Literature DB >> 23075808

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Michelle K Gleason1, Michael R Verneris, Deborah A Todhunter, Bin Zhang, Valarie McCullar, Sophia X Zhou, Angela Panoskaltsis-Mortari, Louis M Weiner, Daniel A Vallera, Jeffrey S Miller.   

Abstract

This study evaluates the mechanism by which bispecific and trispecific killer cell engagers (BiKEs and TriKEs) act to trigger human natural killer (NK) cell effector function and investigates their ability to induce NK cell cytokine and chemokine production against human B-cell leukemia. We examined the ability of BiKEs and TriKEs to trigger NK cell activation through direct CD16 signaling, measuring intracellular Ca²⁺ mobilization, secretion of lytic granules, induction of target cell apoptosis, and production of cytokine and chemokines in response to the Raji cell line and primary leukemia targets. Resting NK cells triggered by the recombinant reagents led to intracellular Ca²⁺ mobilization through direct CD16 signaling. Coculture of reagent-treated resting NK cells with Raji targets resulted in significant increases in NK cell degranulation and target cell death. BiKEs and TriKEs effectively mediated NK cytotoxicity of Raji targets at high and low effector-to-target ratios and maintained functional stability after 24 and 48 hours of culture in human serum. NK cell production of IFN-γ, TNF-α, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-8, macrophage inflammatory protein (MIP)-1α, and regulated and normal T cell expressed and secreted (RANTES) was differentially induced in the presence of recombinant reagents and Raji targets. Moreover, significant increases in NK cell degranulation and enhancement of IFN-γ production against primary acute lymphoblastic leukemia and chronic lymphocytic leukemia targets were induced with reagent treatment of resting NK cells. In conclusion, BiKEs and TriKEs directly trigger NK cell activation through CD16, significantly increasing NK cell cytolytic activity and cytokine production against tumor targets, showing their therapeutic potential for enhancing NK cell immunotherapies for leukemias and lymphomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23075808      PMCID: PMC3519950          DOI: 10.1158/1535-7163.MCT-12-0692

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  45 in total

1.  Natural killer cell signaling pathways.

Authors:  Eric Vivier; Jacques A Nunès; Frédéric Vély
Journal:  Science       Date:  2004-11-26       Impact factor: 47.728

2.  Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production.

Authors:  David G T Hesslein; Rayna Takaki; Michelle L Hermiston; Arthur Weiss; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

3.  Interleukin-12: an immunoregulatory cytokine produced by B cells and antigen-presenting cells.

Authors:  A Sartori; X Ma; G Gri; L Showe; D Benjamin; G Trinchieri
Journal:  Methods       Date:  1997-01       Impact factor: 3.608

Review 4.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma.

Authors:  Gillian M Keating
Journal:  BioDrugs       Date:  2011-02-01       Impact factor: 5.807

Review 6.  Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.

Authors:  Ali R Jazirehi; Benjamin Bonavida
Journal:  Oncogene       Date:  2005-03-24       Impact factor: 9.867

7.  Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

Authors:  Joerg Bruenke; Karin Barbin; Susanne Kunert; Peter Lang; Matthias Pfeiffer; Kristin Stieglmaier; Dietrich Niethammer; Bernhard Stockmeyer; Matthias Peipp; Roland Repp; Thomas Valerius; Georg H Fey
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

8.  Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

Authors:  Michelle K Gleason; Todd R Lenvik; Valarie McCullar; Martin Felices; M Shea O'Brien; Sarah A Cooley; Michael R Verneris; Frank Cichocki; Carol J Holman; Angela Panoskaltsis-Mortari; Toshiro Niki; Mitsuomi Hirashima; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

9.  A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.

Authors:  Christian Kellner; Joerg Bruenke; Julia Stieglmaier; Michael Schwemmlein; Michael Schwenkert; Heiko Singer; Kristin Mentz; Matthias Peipp; Peter Lang; Fuat Oduncu; Bernhard Stockmeyer; Georg H Fey
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

10.  Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells.

Authors:  Yenan T Bryceson; Michael E March; Domingo F Barber; Hans-Gustaf Ljunggren; Eric O Long
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  101 in total

1.  A novel bispecific antibody, BiSS, with potent anti-cancer activities.

Authors:  Bin Dong; Changhua Zhou; Ping He; Jing Li; Siqi Chen; Ji Miao; Qing Li; Zhong Wang
Journal:  Cancer Biol Ther       Date:  2016-02-01       Impact factor: 4.742

2.  Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.

Authors:  Nicole C Smits; Charles L Sentman
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

Review 3.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

4.  Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia.

Authors:  Hyun Don Yun; Dawn K Schirm; Martin Felices; Jeffrey S Miller; Craig E Eckfeldt
Journal:  Blood Adv       Date:  2019-08-27

Review 5.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 6.  Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.

Authors:  Nicole C Smits; Tiffany A Coupet; Claire Godbersen; Charles L Sentman
Journal:  Expert Opin Biol Ther       Date:  2016-06-09       Impact factor: 4.388

7.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.

Authors:  Ronald E Gress; Jeffrey S Miller; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Dan A Landau; Catherine J Wu
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-06       Impact factor: 5.742

Review 8.  Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.

Authors:  Daniel G Guy; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 9.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

10.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors:  Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.